

Drug-Induced Hyperprolactinemia and Hyponatremia - Biological Markers of Unfavorable Evolution in Schizophrenia

Puiu Olivian STOVICEK¹,
Dragoș MARINESCU²,
Liana PĂUNA-CRISTIAN³,
Ileana MARINESCU⁴

¹Lecturer, Department of Pharmacology, Faculty of Nursing, Târgu Jiu Subsidiary, "Titu Maiorescu" University, Bucharest, Romania, puiulolivian@yahoo.com

² Professor, Academy of Medical Sciences of Romania, University of Medicine and Pharmacy of Craiova Branch, Craiova, Romania, marinescu_psy@yahoo.com

³Department of Radiology, Gral Medical Center, Bucharest, Romania, lee_bio@yahoo.com

⁴ Associate Professor, Discipline of Psychiatry, 5th Department, Faculty of Medicine, University of Medicine and Pharmacy of Craiova, Romania, marinescu_psy@yahoo.com

Abstract: *Adverse reactions to psychotropic medication can be considered as risk indicators for an unfavorable evolution of patients with schizophrenia, based on particular pathogenic mechanisms that can be used in the personalized therapeutic approach. The combination of antidepressants with antipsychotic drugs in schizophrenia has a risk of synergistic action of excessive blockade of dopamine receptors, which causes hyperprolactinemia. Primary hyponatremia occurs during pregnancy and can be an important marker for signaling neurodevelopmental abnormalities, while secondary hyponatremia has a major clinical dimension and is induced by psychotropic drugs. The pathogenic mechanisms presented can be objectified by neuroimaging examinations that bring benefits in the diagnostic accuracy and re-evaluation of the therapeutic approach, especially in correlation with the severity of biological markers such as prolactin and sodium. The persistence of high prolactin and low sodium levels is an alarm signal that announces a negative evolution of the patient or a major risk of severe cardiac, metabolic, vascular or renal comorbidities. Recognition of pathogenic mechanisms of neurodevelopment, including ventriculomegaly, hyponatremia, focal cortical dysplasia, hippocampal or temporal lobe lesions, in association with a positive history of neonatal or febrile seizures, requires prophylaxis due to high risk of onset of schizophrenia in childhood. Fetal cortical dysplasia is associated with the risk of neonatal seizures. This vulnerability favors the appearance of febrile convulsions or enuresis with changes in brain structure. Enuresis may be an important marker of neurodevelopmental potential for schizophrenia. Neonatal seizures are correlated with hyponatremia and severe hypertension, which appeared in the third trimester of pregnancy, can trigger eclampsia. Neuroimaging monitoring in patients with neurodevelopmental abnormalities, hyperprolactinemia and primary or secondary hyponatremia, acquires a major importance, being able to delimit the boundary between a functional lesion, potentially reversible, with an irreversible lesion.*

Keywords: schizophrenia, hyperprolactinemia, hyponatremia, dopamine, demyelination.

How to cite: Dumea, E., Efrim, N.D., Petcu, A., Anghel, L., & Puscasu, C.G. (2022). Drug-Induced Hyperprolactinemia and Hyponatremia - Biological Markers of Unfavorable Evolution in Schizophrenia. *BRAIN. Broad Research in Artificial Intelligence and Neuroscience*, 13(1Sup1), 159-174. <https://doi.org/10.18662/brain/13.1Sup1/310>

1. Introduction

Psychopharmacological advances that have aimed to achieve a positive report between the therapeutic benefits and risks of side effects, did not bring the expected results. Schizophrenia is a formidable condition in terms of the most frequently incomplete therapeutic response, but also the risk of various side effects, which can sometimes be severe. Our clinical experience highlights the possibility of addressing the adverse reactions and events of psychotropic medication administered in schizophrenia, as risk indicators for an unfavorable evolution. In some situations, the onset of a side effects may lead the clinical psychopharmacologist to identify particular pathogenic mechanisms that can be used in the personalized therapeutic approach (Radulescu et al., 2020).

Based on these premises, we tried to present the link between hyperprolactinemia, an adverse drug reaction that occurred frequently in daily practice but often minimized, hyponatremia and neurobiological vulnerabilities. This connection can be considered as a risk factor for a negative evolution of schizophrenia, in the short term, but with severe potential, in the long term and with the risk of multiple comorbidities.

2. The consequences of drug-induced hyperprolactinemia

The increase in blood levels of prolactin can be determined directly by the excessive blockade of dopamine D2 receptors in the tuberoinfundibular pathway, as well as indirectly by the increase in serotonin levels which causes a secondary hypodopaminergy. Hyperprolactinemia is amplified by the frequent use of the association between antipsychotics and antidepressants (Torre & Falorni, 2007). It has been shown that depression can occur in about 25% of patients with schizophrenia. Frequently, this depressive symptomatology may constitute a clinical picture of the onset of schizophrenia, leading to delayed diagnosis (Mao & Zhang, 2015). The pharmacological approach with antidepressants in these patients may increase dopamine deficiency, which is why the therapeutic response is incomplete. In this case, the therapeutic adequacy is not observed and the antipsychotic treatment is unreasonably delayed.

From our point of view, although it is considered useful association of antidepressants in the treatment of schizophrenia, there is a risk of synergistic action of inhibiting the dopamine system and excessive blockade of dopamine receptors, which causes a high increase in prolactin levels. Low doses of antipsychotics or selective serotonin reuptake inhibitor (SSRI)

antidepressants that cause hyperprolactinemia or galactorrhea are a pharmacological indicator that suggests a neurodevelopmental anomaly. In this context, the presence of ventriculomegaly at neuroimaging examination, suggests lesions in the subventricular zone, which diminishes the process of neurogenesis (Todd et al., 2018).

The appearance of dysfunctions or microlesions in the hippocampus and hypothalamus, anticipates the risk of frontal atrophy. Frontal lobe lesions may be exacerbated by the imbalance of the gamma-aminobutyric acid (GABA)/glutamate balance and the cytotoxic effect of glutamate, decreased dopamine levels with the onset of hypofrontality syndrome or dopamine D2 receptor blockade. Through these brain mechanisms, prolactin levels rise excessively and correlate with a high risk of severe hyponatremia and thrombotic events (van Zaane et al., 2011) (Figure 1).




Figure 1. Consequences of drug-induced secondary hyponatremia in schizophrenia

Source: van Zaane et al., 2011

Long-term hyperprolactinemia can cause severe changes in heart rhythm as in congenital long QT syndrome (Schwartz et al., 2009), which, although it has a low incidence, becomes a major contraindication to the administration of psychotropic drugs that prolong the QT interval. Specific to the increase in serum prolactin, may be the prolongation of the QT interval characteristic of Brugada syndrome, which is clinically underestimated. This syndrome is associated with severe ventricular

repolarization disorders or the risk of sudden death (Antzelevitch et al., 2003). Brugada syndrome has also been identified in teenage girl with anorexia. If anorexic onset may be correlated with body dysmorphic disorder, it should be considered that chronic anorexia may become circumstance with a major cardiac risk. Consequently, any onset with anorexia manifestations of a psychotic disorder requires a cardiological evaluation and electrocardiographic examination, prior to any psychotropic pharmacological intervention (Docx et al., 2014). Treatment with antipsychotics even at low doses or with antidepressants has a major risk of severe cardiac events, by prolonging the QT interval, with the development of Brugada syndrome or sudden death (Sicouri & Antzelevitch, 2018).

High levels of serum prolactin are also associated with the risk of breast cancer in women (Wang et al., 2016), prostate cancer in men (Crépin et al., 2007), gastrointestinal or endometrial cancer (Lopez-Vicchi & Becu-Villalobos, 2017). Cases of breast cancer have also been reported in men with hyperprolactinemia (Haga et al., 1993). Prostate cancer can have an acinar, neuroendocrine or mixed proliferation, depending on the activity of interleukin-8 (IL-8) and the expression of IL-8 receptors, which can modulate the tumor by autocrine or paracrine pathway (Stănculeanu et al., 2017). Treatment with antipsychotics that cause hyperprolactinemia has an oncological risk due to its action on the prolactin-Janus kinase 2 (JAK2) and signal transducer and activator of transcription 5 (STAT5) signaling pathway, which stimulates cell differentiation and inhibits cell apoptosis (Johnston et al., 2018). In terms of clinical manifestations, the long-term effects of hyperprolactinemia may be galactorrhea and amenorrhea in women or erectile dysfunction with azoospermia in men (Hao et al., 2020).

3. Secondary hyponatremia, induced by psychotropic drugs

Pharmacological treatment with antipsychotics, mood stabilizers and especially with SSRI antidepressants, may have as an adverse reaction hyponatremia, characterized by decreased in serum sodium levels below 135 millimoles per liter (mmol/L) (Cortés & Muñoz, 2018). Symptoms may include apathy, adynamia, fatigue, and are sometimes misinterpreted as belonging to depression. Postpsychotic depression (after an acute episode of schizophrenia) is a hypodopaminergic-type depression that will not respond to antidepressant treatment, but will increase the risk of hyperprolactinemia (Untu et al., 2015).

In patients treated with psychotropic drugs, hyponatremia may be aggravated by the presence of risk factors such as age, early onset of

psychiatric disorder, mild traumatic brain injury (mTBI), oncological risk, the presence of other metabolic or cardiovascular somatic comorbidities (Ather Siddiqui et al., 2018). Given that a relatively small decrease of 10 mmol/L in serum sodium levels in severe hyponatremia (below 125 mmol/L) causes a major risk of coma and death, sodium evaluation becomes an important biological marker indicating re-evaluation of diagnosis and discontinuation of psychotropic treatment. An important problem in clinical practice is the difficulty of the differential clinical diagnosis between hyponatremia and neuroleptic malignant syndrome (NMS), especially if these pathologies are associated with convulsive symptoms (Looi et al., 1995). NMS can also be induced by psychiatric drugs, especially those with antidopaminergic action on dopamine D2 receptors (Ananth et al., 2004).

Rapid therapeutic intervention to correct sodium levels may lead to the onset of myelinolysis syndrome or osmotic demyelination syndrome (Mascarenhas & Jude, 2014), which frequently occurs at the pontine level (Martin, 2004) or extrapontine (Zunga et al., 2015). Extrapontine myelinolysis may be favored by severe renal failure (Tarhan et al., 2004). Patients with cognitive impairment and neurological disorders, especially motor deficit such as parkinsonism, should be evaluated neuroimaging by magnetic resonance imaging (MRI) for early identification of demyelinating changes and should be monitored dynamically for serum sodium levels (Chirita et al., 2012; Mascarenhas & Jude, 2014).

4. Syndrome of inappropriate antidiuretic hormone secretion and diabetes


Antipsychotic-induced dopamine D2 receptor blockade may affect pancreatic β -cells function, promoting the onset of diabetes. Diabetes affects renal function that may worsen in the context of small vessel disease (SVD)-type pathology, which at the renal level becomes an etiopathogenic factor of chronic renal failure. Diabetes and cardiometabolic syndrome can be considered as side effects of some antipsychotic drugs (Holt, 2019). Diabetes treatment in patients with schizophrenia is difficult due to low adherence and compliance to treatment. For this reason, the course of metabolic disease can be severe causing syndrome of inappropriate antidiuretic hormone secretion (SIADH), which amplifies the risk of severe hyponatremia (Harrois & Anstey, 2019). On the other hand, impaired functionality of cerebral small vessels and chronic cerebral ischemia syndrome cause hypothalamic dysfunction and cognitive deficit (Sacuiu et al., 2012). Thalamic dysfunction and SIADH may be exacerbated by

increased serotonin levels induced by proserotonergic antidepressant drugs (Pillai et al., 2011).

5. Neuroimaging evaluation

The pathogenic mechanisms presented can be objectified by neuroimaging examinations, which can bring benefits in the diagnostic accuracy and re-evaluation of the therapeutic approach, especially in correlation with the severity of biological markers (Ciubara et al., 2015). It is important to monitor biological markers over time, especially prolactin and sodium, their severe change being an indication for neuroimaging examination. MRI assessment can identify pontine demyelinating changes (Figure 2). Extrapontine demyelination can be located in the corpus callosum (Figure 3) or in the cerebellum (Figure 4). Ventriculomegaly can be highlighted following atrophy of the subventricular zone and periventricular leukomalacia (Figure 5). SVD changes in the brain can be easily identified by white matter hyperintensities at the periventricular level (Figure 6).



In case of persistent hyperprolactinemia, the diagnosis of prolactinoma should be eliminated. Under conditions of psychotropic treatments that induce massive prolactin release, an enlargement of the pituitary gland due to hyperfunction was found (Figure 7). The use of these neuroimaging markers in times of uncertainty diagnose or lack of therapeutic response may be of major importance to the patient. The occurrence of pontine myelinolysis can help the differential diagnosis with NMS and requires the rebalancing of hyponatremia, accompanied or not by extrapontine demyelination syndrome.



Source: Authors' own conception

Figure 2. MRI image with oval lesion on pons that has hyperintense signal on fluid-attenuated inversion recovery (FLAIR) sequence, symmetrical, with no mass effect (central pontine myelinolysis).

Figure 3. MRI image with demyelinating lesion of the corpus callosum, with FLAIR hyperintense signal.



Source: Authors' own conception

Figure 4. Axial FLAIR MRI image with a consistent with bilateral cerebellar white matter lesions (infratentorial demyelinating lesion).

Figure 5. Axial T2 MRI image demonstrate marked dilatation of the ventricular system (ventriculomegaly); there is no transependymal edema (chronic dilatation).




Figure 6. MRI image with multiple periventricular white matter lesions (demyelinating lesions).




Figure 7. MRI image of the pituitary-dynamic contrast enhanced sequence demonstrates a mass, in the left pituitary gland, with remodeling of the sellar floor.

Source: Authors' own conception

6. Primary hyponatremia in pregnancy

If the secondary hyponatremia induced by psychotropic drugs has a major clinical dimension, the primary hyponatremia that appeared since the gestational period can be an important marker for signaling neurodevelopmental abnormalities. Frequently, the pregnant woman may have different types of hypertension: pre-existing pregnancy and under treatment, started during pregnancy (gestational hypertension) or in the third trimester of pregnancy when it can announce the risk of eclampsia.

Pregnant women with hypertension treated with diuretics or SSRI antidepressants for pre-pregnancy depression may have low serum sodium from the first weeks of pregnancy (Braunthal & Brateanu, 2019). At the same time, pregnancy predisposes to changes in plasma osmolality that may occur in early pregnancy and announces vulnerability to the onset of SIADH (Sutton et al., 1993). The presence of kidney disease amplifies this risk and serum sodium values require strict monitoring, due to the constant decrease that can cause severe hyponatremia. Therapy with antihypertensive drugs can trigger gestational hypotension, and by crossing the placenta, at the level

of cerebral neurodevelopment of the fetus, manifestations of focal cortical dysplasia may occur (Kabat & Król, 2012).

At the same time, intrauterine growth restriction (IUGR) pathology is installed, which favors premature birth and obstetric complications with risk of maternal death. Fetal growth restrictions cause astrocyte dysfunction which, in a first stage, tries to compensate for the effects of hyponatremia in the fetal brain. When this compensating capacity is exceeded, the phenomenon of microglial activation is triggered. Activation of the M1 phenotype is associated with hyperpermeability lesions of the blood-brain barrier (BBB) that may trigger epileptic seizures in childhood (Orihuela et al., 2016). On the other hand, BBB dysfunction caused by hyperglutamatergia, simultaneously with depression and non-responsiveness to oncological treatment, may be an alarm signal for the occurrence of brain metastases in prostate cancer (Marinescu et al., 2019). Microglial activation increases neuronal destruction by proinflammatory and cytokine mechanisms, with the occurrence of cognitive deficit, especially in patients who had mTBI in childhood (Ciobotea et al., 2016; Stovicek et al., 2020). In this way we can explain the neurodegenerative symptoms of schizophrenia.

Imbalance of the M1/M2 phenotypic balance causes hippocampal and temporal lobe atrophies in the fetal brain (Figure 8). These lesions cause temporal lobe epilepsy or schizophrenia-like psychosis in childhood or adolescence (Finegersh et al., 2011). Fetal cortical dysplasia is associated with the risk of neonatal seizures. In young children this vulnerability favors the appearance of febrile convulsions or enuresis with changes in brain structure and electroencephalogram examination (Figure 9).




Figure 8. Coronal FLAIR sequence MRI image demonstrates moderate degree of volume loss of the left temporal lobe; the temporal horns are dilated, with volume loss of the hippocampus. *Source:* Authors' own conception




Figure 9. Consequences of primary hyponatremia, as a neurodevelopmental abnormality

Source: Finegersh et al., 2011

Enuresis may be an important marker of neurodevelopmental potential for schizophrenia, along with neuroimaging changes that highlight gray matter losses in the frontal lobe (Hyde et al., 2008). Neonatal seizures are also associated with hyponatremia (Pasi et al., 2019). Hypertension in the third trimester of pregnancy, with severe evolution can trigger eclampsia, which can be a risk marker for the further development of schizophrenia (Cannon et al., 2002), while pregnant patients with schizophrenia have a higher risk of pre-eclampsia and thrombotic events (Raimondi & Sheiner, 2015).

7. Conclusions

The pathogenic models presented have clinical applicability, patients with schizophrenia needing to identify biological indicators such as prolactin and sodium, before administering psychotropic drugs. Monitoring must be done continuously, the persistence of high prolactin values and low sodium levels being an alarm signal that announces a negative evolution of the patient or a major risk of severe cardiac, metabolic, vascular or renal comorbidities. Neuroimaging monitoring in patients with neurodevelopmental abnormalities, hyperprolactinemia and primary or secondary hyponatremia, acquires a major importance, being able to delimit the boundary between a functional lesion, potentially reversible, with a lesion, irreversible. Recognition of pathogenic neurodevelopmental mechanisms that include ventriculomegaly, hyponatremia, focal cortical dysplasia, hippocampal or temporal lobe lesions, in association with a positive history of neonatal or febrile seizures, requires prophylactic measures due to the high risk of onset of schizophrenia in childhood or adolescence. Prolactin monitoring should become a routine for the clinical psychiatrist, being a short-term or medium-term predictive indicator for the unfavorable evolution of schizophrenia, with the appearance of cognitive impairment and hypofrontality syndrome, accompanied by negative symptoms and depression. Cardiovascular risk is represented by severe heart rhythm abnormalities or thrombotic risk. The association of antidepressants with antipsychotics in the therapy of schizophrenia brings limited therapeutic benefits, but the medium-term and long-term risks are major and contribute to unfavorable evolution, somatic comorbidities and decreased quality of life of the patient.

References

- Ananth, J., Aduri, K., Parameswaran, S., & Gunatilake, S. (2004). Neuroleptic malignant syndrome: Risk factors, pathophysiology, and treatment. *Acta Neuropsychiatrica*, 16(4), 219-228. <https://doi.org/10.1111/j.0924-2708.2004.00085.x>
- Antzelevitch, C., Brugada, P., Brugada, J., Brugada, R., Towbin, J. A., & Nademanee, K. (2003). Brugada syndrome: 1992-2002: a historical perspective. *Journal of the American College of Cardiology*, 41(10), 1665-1671. [https://doi.org/10.1016/s0735-1097\(03\)00310-3](https://doi.org/10.1016/s0735-1097(03)00310-3)
- Ather Siddiqui, J., Qureshi, S.F., & Al Zaharani, A. (2018). Psychotropic-Induced Hyponatremia: A Review. *Psychiatry and Behavioral Sciences* 8(4), 213-221. <https://doi.org/10.5455/PBS.20180324094723>
- Braunthal, S., & Brateanu, A. (2019). Hypertension in pregnancy: Pathophysiology and treatment. *SAGE open medicine*, 7. <https://doi.org/10.1177/2050312119843700>
- Cannon, M., Jones, P. B., & Murray, R. M. (2002). Obstetric complications and schizophrenia: historical and meta-analytic review. *The American journal of psychiatry*, 159(7), 1080-1092. <https://doi.org/10.1176/appi.ajp.159.7.1080>
- Chirita, R., Sacuiu, I., Burlea, A., & Chirita, V. (2012). The role of nitric oxide inhibitors in treatment on symptom severity and cognitive deficits in schizophrenia. *International Journal of Neuropsychopharmacology*, 15 (1 Sup 1) 113-113. <https://doi.org/10.1017/S1461145712000508>
- Ciobotea, D., Vlaicu, B., Ciubara, A., Duica, C. L., Cotocel, C., Antohi, V., & Pirlog, M. C. (2016). Visual Impairment in the Elderly and its Influence on the Quality of Life. *Revista de Cercetare si Interventie Sociala*, 54, 66-74. <https://www.rcis.ro/ro/section1/142-volumul-54-2016-septembrie/2293-visual-impairment-in-the-elderly-and-its-influence-on-the-quality-of-life.html>
- Ciubara, A., Cartas, N., Burlea, L. S., Chirita, R., Ciubara, B. A., Untu, I., & Iliescu, D. B. (2015). The Relationship Between Schizophrenia and Criminality. *European Psychiatry*, 30(S1), 1-1. [https://doi.org/10.1016/S0924-9338\(15\)30603-9](https://doi.org/10.1016/S0924-9338(15)30603-9)
- Cortés, M., & Muñoz, P. (2018). *Hyponatremia and Psychotropic Drugs*. In Usman Mahmood (Ed.), *Fluid and Electrolyte Disorders*. Intechopen. <https://doi.org/10.5772/intechopen.79029>
- Crépin, A., Bidaux, G., Vanden-Abee, F., Dewailly, E., Goffin, V., Prevarskaya, N., & Slomianny, C. (2007). Prolactin stimulates prostate cell proliferation by increasing endoplasmic reticulum content due to SERCA 2b over-expression. *The Biochemical journal*, 401(1), 49-55. <https://doi.org/10.1042/BJ20060870>

- Docx, M., Loeys, B., Simons, A., Gewillig, M., Proost, D., Van Laer, L., & Mertens, L. (2014). Intermittent Brugada syndrome in an anorexic adolescent girl. *Journal of cardiology cases*, 10(3), 81–84. <https://doi.org/10.1016/j.jccase.2014.03.012>
- Finegersh, A., Avedissian, C., Shamim, S., Dustin, I., Thompson, P. M., & Theodore, W. H. (2011). Bilateral hippocampal atrophy in temporal lobe epilepsy: effect of depressive symptoms and febrile seizures. *Epilepsia*, 52(4), 689–697. <https://doi.org/10.1111/j.1528-1167.2010.02928.x>
- Haga, S., Watanabe, O., Shimizu, T., Iida, T., Imamura, H., Kajiwar, T., & Fujibayashi, M. (1993). Breast cancer in a male patient with prolactinoma. *Surgery today*, 23(3), 251–255. <https://doi.org/10.1007/BF00309236>
- Hao, S., Huang, M., Tian, W., Chen, Y., Zhao, J., & Luo, D. (2020). Whole Exome Sequencing in the Male Breast Cancer with Prolactinoma: A Case Report and Literature Review. *Journal of breast cancer*, 23(6), 656–664. <https://doi.org/10.4048/jbc.2020.23.e63>
- Harrois, A., & Anstey, J. R. (2019). Diabetes Insipidus and Syndrome of Inappropriate Antidiuretic Hormone in Critically Ill Patients. *Critical care clinics*, 35(2), 187–200. <https://doi.org/10.1016/j.ccc.2018.11.00>
- Holt, R. (2019). Association Between Antipsychotic Medication Use and Diabetes. *Current diabetes reports*, 19(10), 96. <https://doi.org/10.1007/s11892-019-1220-8>
- Hyde, T. M., Deep-Soboslay, A., Iglesias, B., Callicott, J. H., Gold, J. M., Meyer-Lindenberg, A., Honea, R. A., Bigelow, L. B., Egan, M. F., Emsellem, E. M., & Weinberger, D. R. (2008). Enuresis as a premorbid developmental marker of schizophrenia. *Brain: a journal of neurology*, 131(9), 2489–2498. <https://doi.org/10.1093/brain/awn167>
- Johnston, A. N., Bu, W., Hein, S., Garcia, S., Camacho, L., Xue, L., Qin, L., Nagi, C., Hilsenbeck, S. G., Kapali, G., J., Podsypanina, K., Nangia, J., & Li, Y. (2018). Hyperprolactinemia-inducing antipsychotics increase breast cancer risk by activating JAK-STAT5 in precancerous lesions. *Breast cancer research: BCR*, 20(1), 42. <https://doi.org/10.1186/s13058-018-0969-z>
- Kabat, J., & Król, P. (2012). Focal cortical dysplasia - review. *Polish journal of radiology*, 77(2), 35–43. <https://doi.org/10.12659/pjr.882968>
- Looi, J. C., Cubis, J. C., & Saboisky, J. (1995). Hyponatremia, convulsions and neuroleptic malignant syndrome in a male with schizoaffective disorder. *The Australian and New Zealand journal of psychiatry*, 29(4), 683–687. <https://doi.org/10.3109/00048679509064986>
- Lopez-Vicchi, F., & Becu-Villalobos, D. (2017). Prolactin: The Bright and the Dark Side. *Endocrinology*, 158(6), 1556–1559. <https://doi.org/10.1210/en.2017-00184>

- Mao, Y. M., & Zhang, M. D. (2015). Augmentation with antidepressants in schizophrenia treatment: benefit or risk. *Neuropsychiatric disease and treatment*, 11, 701–713. <https://doi.org/10.2147/NDT.S62266>
- Marinescu, I., Schenker, R. A., Stovicek, P. O., Marinescu, D., Ciobanu, C. F., Papacoccea, S. I., Manea, M. C., Papacoccea, R. I., Manea, M., Chirita, R., & Ciobanu, A. M. (2019). Biochemical Factors Involved in the Unfavorable Evolution of Prostate Cancer. *Revista de Chimie*, 70(9), 3343–3347. <https://doi.org/10.37358/RC.19.9.7546>
- Martin, R. J. (2004). Central pontine and extrapontine myelinolysis: the osmotic demyelination syndromes. *Journal of neurology, neurosurgery, and psychiatry*, 75(Sup. 3), 22–28. <https://doi.org/10.1136/jnnp.2004.045906>
- Mascarenhas, J. V., & Jude, E. B. (2014). Central pontine myelinolysis: electrolytes and beyond. *BMJ Case reports*, bcr2013203516. <https://doi.org/10.1136/bcr-2013-203516>
- Orihuela, R., McPherson, C. A., & Harry, G. J. (2016). Microglial M1/M2 polarization and metabolic states. *British journal of pharmacology*, 173(4), 649–665. <https://doi.org/10.1111/bph.13139>
- Pasi, R., Roy, B., Ravi, K., & Chacham, S. (2019). Profile of Neonatal Seizures and its Correlation with Serum Sodium Levels: A Prospective Cross-sectional Study. *Journal of Clinical and Diagnostic Research*, 13(4), SC04-SC07. <https://doi.org/10.7860/JCDR/2019/40485.12760>
- Pillai, B. P., Unnikrishnan, A. G., & Pavithran, P. V. (2011). Syndrome of inappropriate antidiuretic hormone secretion: Revisiting a classical endocrine disorder. *Indian journal of endocrinology and metabolism*, 15(Suppl3), 208–215. <https://doi.org/10.4103/2230-8210.84870>
- Rădulescu, I. D., Ciubara, A. B., Moraru, C., Burlea, S. L., & Ciubară, A. (2020). Evaluating the Impact of Dissociation in Psychiatric Disorders. *BRAIN. Broad Research in Artificial Intelligence and Neuroscience*, 11(3Sup1), 163–174. <https://doi.org/10.18662/brain/11.3Sup1/132>
- Raimondi, A., & Sheiner, E. (2015). Pregnant women with schizophrenia are at higher risk of pre-eclampsia, venous thromboembolism and adverse neonatal outcomes. *Evidence-based nursing*, 18(2), 39–40. <https://doi.org/10.1136/eb-2014-101902>
- Sacuiu, I., Chirita, V., Burlea, A., & Chirita, R. (2012). The effect of the atypical antipsychotics on cognitive deficit in schizophrenia. *International Journal of Neuropsychopharmacology*, 15, 61–61. <https://doi.org/10.1017/S1461145712000508>
- Schwartz, P. J., Stramba-Badiale, M., Crotti, L., Pedrazzini, M., Besana, A., Bosi, G., Gabbarini, F., Goulene, K., Insolia, R., Mannarino, S., Mosca, F., Nespoli, L., Rimini, A., Rosati, E., Salice, P., & Spazzolini, C. (2009). *Prevalence of the*

- congenital long-QT syndrome. Circulation*, 120(18), 1761–1767.
<https://doi.org/10.1161/circulationaha.109.863209>
- Sicouri, S., & Antzelevitch, C. (2018). Mechanisms Underlying the Actions of Antidepressant and Antipsychotic Drugs That Cause Sudden Cardiac Arrest. *Arrhythmia & electrophysiology review*, 7(3), 199–209.
<https://doi.org/10.15420/aer.2018.29.2>
- Stănculeanu, D. L., Ardeleanu, C. M., Zob, D. L., Mihăilă, R. I., Toma, O. C., Simion, L., Stovicek, P. O., & Schenker, M. (2017). Adenocarcinoma versus pancreatic neuroendocrine tumor - case report. *Romanian journal of morphology and embryology*, 58(3), 1091–1097.
<https://rjme.ro/RJME/resources/files/58031710911097.pdf>
- Stovicek, P. O., Friedmann, C., Marinescu, D., Văduva, I. A., Bondari, S., Trifu, S. C., & Marinescu, I. (2020). Mild TBI in the elderly - risk factor for rapid cognitive impairment in Alzheimer's disease. *Romanian journal of morphology and embryology*, 61(1), 61–72. <https://doi.org/10.47162/RJME.61.1.07>
- Sutton, R. A., Schonholzer, K., & Kassen, B. O. (1993). Transient syndrome of inappropriate antidiuretic hormone secretion during pregnancy. *American journal of kidney diseases: the official journal of the National Kidney Foundation*, 21(4), 444–445. [https://doi.org/10.1016/s0272-6386\(12\)80275-7](https://doi.org/10.1016/s0272-6386(12)80275-7)
- Tarhan, N. C., Agildere, A. M., Benli, U. S., Ozdemir, F. N., Aytekin, C., & Can, U. (2004). Osmotic demyelination syndrome in end-stage renal disease after recent hemodialysis: MRI of the brain. *American journal of roentgenology*, 182(3), 809–816. <https://doi.org/10.2214/ajr.182.3.1820809>
- Todd, K. L., Brighton, T., Norton, E. S., Schick, S., Elkins, W., Pletnikova, O., Fortinsky, R. H., Troncoso, J. C., Molfese, P. J., Resnick, S. M., Conover, J. C., & Alzheimer's Disease Neuroimaging Initiative (2018). Ventricular and Periventricular Anomalies in the Aging and Cognitively Impaired Brain. *Frontiers in aging neuroscience*, 9, 445.
<https://doi.org/10.3389/fnagi.2017.00445>
- Torre, D. L., & Falorni, A. (2007). Pharmacological causes of hyperprolactinemia. *Therapeutics and clinical risk management*, 3(5), 929–951.
- Untu, I., Chirita, R., Bulgaru-Iliescu, D., Chirila, B.D., Ciubara, A., & Burlea, S.L. (2015). Ethical Implications of Bio-Psycho-Social Transformations Entailed by the Aging Process. *Revista de Cercetare si Interventie Sociala*, 48, 216-225. <https://www.rcis.ro/ro/section1/136-volumul-482015martie/2161-ethical-implications-of-bio-psycho-social-transformations-entailed-by-the-aging-process.html>
- van Zaane, B., Squizzato, A., Reuwer, A. Q., van Zanten, A. P., Twickler, M. T., Dekkers, O. M., Cannegieter, S. C., Büller, H. R., Gerdes, V. E., & Brandjes, D. P. (2011). Prolactin and venous thrombosis: indications for a

- novel risk factor? *Arteriosclerosis, thrombosis, and vascular biology*, 31(3), 672–677. <https://doi.org/10.1161/ATVBAHA.110.209569>
- Wang, M., Wu, X., Chai, F., Zhang, Y., & Jiang, J. (2016). Plasma prolactin and breast cancer risk: a meta- analysis. *Scientific reports*, 6, 25998. <https://doi.org/10.1038/srep25998>
- Zunga, P. M., Farooq, O., Dar, M. I., Dar, I. H., Rashid, S., Rather, A. Q., Basu, J. A., Ashraf, M., & Bhat, J. A. (2015). Extra pontine osmotic demyelination syndrome. *Annals of neurosciences*, 22(1), 51–53. <https://doi.org/10.5214/ans.0972.7531.220212>